Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration
Comparative assessment of treatment results in paediatric hepatoblastoma trials has been hampered by small patient numbers and the use of multiple disparate staging systems by the four major trial groups. To address this challenge, we formed a global coalition, the Children's Hepatic tumors Int...
Saved in:
| Published in | The lancet oncology Vol. 18; no. 1; pp. 122 - 131 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.01.2017
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1470-2045 1474-5488 1474-5488 |
| DOI | 10.1016/S1470-2045(16)30598-8 |
Cover
| Abstract | Comparative assessment of treatment results in paediatric hepatoblastoma trials has been hampered by small patient numbers and the use of multiple disparate staging systems by the four major trial groups. To address this challenge, we formed a global coalition, the Children's Hepatic tumors International Collaboration (CHIC), with the aim of creating a common approach to staging and risk stratification in this rare cancer.
The CHIC steering committee—consisting of leadership from the four major cooperative trial groups (the International Childhood Liver Tumours Strategy Group, Children's Oncology Group, the German Society for Paediatric Oncology and Haematology, and the Japanese Study Group for Paediatric Liver Tumours)—created a shared international database that includes comprehensive data from 1605 children treated in eight multicentre hepatoblastoma trials over 25 years. Diagnostic factors found to be most prognostic on initial analysis were PRETreatment EXTent of disease (PRETEXT) group; age younger than 3 years, 3–7 years, and 8 years or older; α fetoprotein (AFP) concentration of 100 ng/mL or lower and 101–1000 ng/mL; and the PRETEXT annotation factors metastatic disease (M), macrovascular involvement of all hepatic veins (V) or portal bifurcation (P), contiguous extrahepatic tumour (E), multifocal tumour (F), and spontaneous rupture (R). We defined five clinically relevant backbone groups on the basis of established prognostic factors: PRETEXT I/II, PRETEXT III, PRETEXT IV, metastatic disease, and AFP concentration of 100 ng/mL or lower at diagnosis. We then carried the additional factors into a hierarchical backwards elimination multivariable analysis and used the results to create a new international staging system.
Within each backbone group, we identified constellations of factors that were most predictive of outcome in that group. The robustness of candidate models was then interrogated using the bootstrapping procedure. Using the clinically established PRETEXT groups I, II, III, and IV as our stems, we created risk stratification trees based on 5 year event-free survival and clinical applicability. We defined and adopted four risk groups: very low, low, intermediate, and high.
We have created a unified global approach to risk stratification in children with hepatoblastoma on the basis of rigorous statistical interrogation of what is, to the best of our knowledge, the largest dataset ever assembled for this rare paediatric tumour. This achievement provides the structural framework for further collaboration and prospective international cooperative study, such as the Paediatric Hepatic International Tumour Trial (PHITT).
European Network for Cancer Research in Children and Adolescents, funded through the Framework Program 7 of the European Commission (grant number 261474); Children's Oncology Group CureSearch grant contributed by the Hepatoblastoma Foundation; Practical Research for Innovative Cancer Control and Project Promoting Clinical Trials for Development of New Drugs and Medical Devices, Japan Agency for Medical Research; and Swiss Cancer Research grant. |
|---|---|
| AbstractList | Comparative assessment of treatment results in paediatric hepatoblastoma trials has been hampered by small patient numbers and the use of multiple disparate staging systems by the four major trial groups. To address this challenge, we formed a global coalition, the Children's Hepatic tumors International Collaboration (CHIC), with the aim of creating a common approach to staging and risk stratification in this rare cancer.
The CHIC steering committee-consisting of leadership from the four major cooperative trial groups (the International Childhood Liver Tumours Strategy Group, Children's Oncology Group, the German Society for Paediatric Oncology and Haematology, and the Japanese Study Group for Paediatric Liver Tumours)-created a shared international database that includes comprehensive data from 1605 children treated in eight multicentre hepatoblastoma trials over 25 years. Diagnostic factors found to be most prognostic on initial analysis were PRETreatment EXTent of disease (PRETEXT) group; age younger than 3 years, 3-7 years, and 8 years or older; α fetoprotein (AFP) concentration of 100 ng/mL or lower and 101-1000 ng/mL; and the PRETEXT annotation factors metastatic disease (M), macrovascular involvement of all hepatic veins (V) or portal bifurcation (P), contiguous extrahepatic tumour (E), multifocal tumour (F), and spontaneous rupture (R). We defined five clinically relevant backbone groups on the basis of established prognostic factors: PRETEXT I/II, PRETEXT III, PRETEXT IV, metastatic disease, and AFP concentration of 100 ng/mL or lower at diagnosis. We then carried the additional factors into a hierarchical backwards elimination multivariable analysis and used the results to create a new international staging system.
Within each backbone group, we identified constellations of factors that were most predictive of outcome in that group. The robustness of candidate models was then interrogated using the bootstrapping procedure. Using the clinically established PRETEXT groups I, II, III, and IV as our stems, we created risk stratification trees based on 5 year event-free survival and clinical applicability. We defined and adopted four risk groups: very low, low, intermediate, and high.
We have created a unified global approach to risk stratification in children with hepatoblastoma on the basis of rigorous statistical interrogation of what is, to the best of our knowledge, the largest dataset ever assembled for this rare paediatric tumour. This achievement provides the structural framework for further collaboration and prospective international cooperative study, such as the Paediatric Hepatic International Tumour Trial (PHITT).
European Network for Cancer Research in Children and Adolescents, funded through the Framework Program 7 of the European Commission (grant number 261474); Children's Oncology Group CureSearch grant contributed by the Hepatoblastoma Foundation; Practical Research for Innovative Cancer Control and Project Promoting Clinical Trials for Development of New Drugs and Medical Devices, Japan Agency for Medical Research; and Swiss Cancer Research grant. Background Comparative assessment of treatment results in paediatric hepatoblastoma trials has been hampered by small patient numbers and the use of multiple disparate staging systems by the four major trial groups. To address this challenge, we formed a global coalition, the Children's Hepatic tumors International Collaboration (CHIC), with the aim of creating a common approach to staging and risk stratification in this rare cancer. Methods The CHIC steering committee-consisting of leadership from the four major cooperative trial groups (the International Childhood Liver Tumours Strategy Group, Children's Oncology Group, the German Society for Paediatric Oncology and Haematology, and the Japanese Study Group for Paediatric Liver Tumours)-created a shared international database that includes comprehensive data from 1605 children treated in eight multicentre hepatoblastoma trials over 25 years. Diagnostic factors found to be most prognostic on initial analysis were PRETreatment EXTent of disease (PRETEXT) group; age younger than 3 years, 3-7 years, and 8 years or older; alpha fetoprotein (AFP) concentration of 100 ng/mL or lower and 101-1000 ng/mL; and the PRETEXT annotation factors metastatic disease (M), macrovascular involvement of all hepatic veins (V) or portal bifurcation (P), contiguous extrahepatic tumour (E), multifocal tumour (F), and spontaneous rupture (R). We defined five clinically relevant backbone groups on the basis of established prognostic factors: PRETEXT I/II, PRETEXT III, PRETEXT IV, metastatic disease, and AFP concentration of 100 ng/mL or lower at diagnosis. We then carried the additional factors into a hierarchical backwards elimination multivariable analysis and used the results to create a new international staging system. Results Within each backbone group, we identified constellations of factors that were most predictive of outcome in that group. The robustness of candidate models was then interrogated using the bootstrapping procedure. Using the clinically established PRETEXT groups I, II, III, and IV as our stems, we created risk stratification trees based on 5 year event-free survival and clinical applicability. We defined and adopted four risk groups: very low, low, intermediate, and high. Interpretation We have created a unified global approach to risk stratification in children with hepatoblastoma on the basis of rigorous statistical interrogation of what is, to the best of our knowledge, the largest dataset ever assembled for this rare paediatric tumour. This achievement provides the structural framework for further collaboration and prospective international cooperative study, such as the Paediatric Hepatic International Tumour Trial (PHITT). Funding European Network for Cancer Research in Children and Adolescents, funded through the Framework Program 7 of the European Commission ( grant number 261474 ); Children's Oncology Group CureSearch grant contributed by the Hepatoblastoma Foundation; Practical Research for Innovative Cancer Control and Project Promoting Clinical Trials for Development of New Drugs and Medical Devices, Japan Agency for Medical Research; and Swiss Cancer Research grant. Comparative assessment of treatment results in paediatric hepatoblastoma trials has been hampered by small patient numbers and the use of multiple disparate staging systems by the four major trial groups. To address this challenge, we formed a global coalition, the Children's Hepatic tumors International Collaboration (CHIC), with the aim of creating a common approach to staging and risk stratification in this rare cancer.BACKGROUNDComparative assessment of treatment results in paediatric hepatoblastoma trials has been hampered by small patient numbers and the use of multiple disparate staging systems by the four major trial groups. To address this challenge, we formed a global coalition, the Children's Hepatic tumors International Collaboration (CHIC), with the aim of creating a common approach to staging and risk stratification in this rare cancer.The CHIC steering committee-consisting of leadership from the four major cooperative trial groups (the International Childhood Liver Tumours Strategy Group, Children's Oncology Group, the German Society for Paediatric Oncology and Haematology, and the Japanese Study Group for Paediatric Liver Tumours)-created a shared international database that includes comprehensive data from 1605 children treated in eight multicentre hepatoblastoma trials over 25 years. Diagnostic factors found to be most prognostic on initial analysis were PRETreatment EXTent of disease (PRETEXT) group; age younger than 3 years, 3-7 years, and 8 years or older; α fetoprotein (AFP) concentration of 100 ng/mL or lower and 101-1000 ng/mL; and the PRETEXT annotation factors metastatic disease (M), macrovascular involvement of all hepatic veins (V) or portal bifurcation (P), contiguous extrahepatic tumour (E), multifocal tumour (F), and spontaneous rupture (R). We defined five clinically relevant backbone groups on the basis of established prognostic factors: PRETEXT I/II, PRETEXT III, PRETEXT IV, metastatic disease, and AFP concentration of 100 ng/mL or lower at diagnosis. We then carried the additional factors into a hierarchical backwards elimination multivariable analysis and used the results to create a new international staging system.METHODSThe CHIC steering committee-consisting of leadership from the four major cooperative trial groups (the International Childhood Liver Tumours Strategy Group, Children's Oncology Group, the German Society for Paediatric Oncology and Haematology, and the Japanese Study Group for Paediatric Liver Tumours)-created a shared international database that includes comprehensive data from 1605 children treated in eight multicentre hepatoblastoma trials over 25 years. Diagnostic factors found to be most prognostic on initial analysis were PRETreatment EXTent of disease (PRETEXT) group; age younger than 3 years, 3-7 years, and 8 years or older; α fetoprotein (AFP) concentration of 100 ng/mL or lower and 101-1000 ng/mL; and the PRETEXT annotation factors metastatic disease (M), macrovascular involvement of all hepatic veins (V) or portal bifurcation (P), contiguous extrahepatic tumour (E), multifocal tumour (F), and spontaneous rupture (R). We defined five clinically relevant backbone groups on the basis of established prognostic factors: PRETEXT I/II, PRETEXT III, PRETEXT IV, metastatic disease, and AFP concentration of 100 ng/mL or lower at diagnosis. We then carried the additional factors into a hierarchical backwards elimination multivariable analysis and used the results to create a new international staging system.Within each backbone group, we identified constellations of factors that were most predictive of outcome in that group. The robustness of candidate models was then interrogated using the bootstrapping procedure. Using the clinically established PRETEXT groups I, II, III, and IV as our stems, we created risk stratification trees based on 5 year event-free survival and clinical applicability. We defined and adopted four risk groups: very low, low, intermediate, and high.RESULTSWithin each backbone group, we identified constellations of factors that were most predictive of outcome in that group. The robustness of candidate models was then interrogated using the bootstrapping procedure. Using the clinically established PRETEXT groups I, II, III, and IV as our stems, we created risk stratification trees based on 5 year event-free survival and clinical applicability. We defined and adopted four risk groups: very low, low, intermediate, and high.We have created a unified global approach to risk stratification in children with hepatoblastoma on the basis of rigorous statistical interrogation of what is, to the best of our knowledge, the largest dataset ever assembled for this rare paediatric tumour. This achievement provides the structural framework for further collaboration and prospective international cooperative study, such as the Paediatric Hepatic International Tumour Trial (PHITT).INTERPRETATIONWe have created a unified global approach to risk stratification in children with hepatoblastoma on the basis of rigorous statistical interrogation of what is, to the best of our knowledge, the largest dataset ever assembled for this rare paediatric tumour. This achievement provides the structural framework for further collaboration and prospective international cooperative study, such as the Paediatric Hepatic International Tumour Trial (PHITT).European Network for Cancer Research in Children and Adolescents, funded through the Framework Program 7 of the European Commission (grant number 261474); Children's Oncology Group CureSearch grant contributed by the Hepatoblastoma Foundation; Practical Research for Innovative Cancer Control and Project Promoting Clinical Trials for Development of New Drugs and Medical Devices, Japan Agency for Medical Research; and Swiss Cancer Research grant.FUNDINGEuropean Network for Cancer Research in Children and Adolescents, funded through the Framework Program 7 of the European Commission (grant number 261474); Children's Oncology Group CureSearch grant contributed by the Hepatoblastoma Foundation; Practical Research for Innovative Cancer Control and Project Promoting Clinical Trials for Development of New Drugs and Medical Devices, Japan Agency for Medical Research; and Swiss Cancer Research grant. Comparative assessment of treatment results in paediatric hepatoblastoma trials has been hampered by small patient numbers and the use of multiple disparate staging systems by the four major trial groups. To address this challenge, we formed a global coalition, the Children's Hepatic tumors International Collaboration (CHIC), with the aim of creating a common approach to staging and risk stratification in this rare cancer. Methods The CHIC steering committee--consisting of leadership from the four major cooperative trial groups (the International Childhood Liver Tumours Strategy Group, Children's Oncology Group, the German Society for Paediatric Oncology and Haematology, and the Japanese Study Group for Paediatric Liver Tumours)--created a shared international database that includes comprehensive data from 1605 children treated in eight multicentre hepatoblastoma trials over 25 years. Diagnostic factors found to be most prognostic on initial analysis were PRETreatment EXTent of disease (PRETEXT) group; age younger than 3 years, 3-7 years, and 8 years or older; α fetoprotein (AFP) concentration of 100 ng/mL or lower and 101-1000 ng/mL; and the PRETEXT annotation factors metastatic disease (M), macrovascular involvement of all hepatic veins (V) or portal bifurcation (P), contiguous extrahepatic tumour (E), multifocal tumour (F), and spontaneous rupture (R). We defined five clinically relevant backbone groups on the basis of established prognostic factors: PRETEXT I/II, PRETEXT III, PRETEXT IV, metastatic disease, and AFP concentration of 100 ng/mL or lower at diagnosis. We then carried the additional factors into a hierarchical backwards elimination multivariable analysis and used the results to create a new international staging system. Results Within each backbone group, we identified constellations of factors that were most predictive of outcome in that group. The robustness of candidate models was then interrogated using the bootstrapping procedure. Using the clinically established PRETEXT groups I, II, III, and IV as our stems, we created risk stratification trees based on 5 year event-free survival and clinical applicability. We defined and adopted four risk groups: very low, low, intermediate, and high. Interpretation We have created a unified global approach to risk stratification in children with hepatoblastoma on the basis of rigorous statistical interrogation of what is, to the best of our knowledge, the largest dataset ever assembled for this rare paediatric tumour. This achievement provides the structural framework for further collaboration and prospective international cooperative study, such as the Paediatric Hepatic International Tumour Trial (PHITT). Funding European Network for Cancer Research in Children and Adolescents, funded through theFramework Program 7 of the European Commission(grant number 261474); Children's Oncology Group CureSearch grant contributed by the Hepatoblastoma Foundation; Practical Research for Innovative Cancer Control and Project Promoting Clinical Trials for Development of New Drugs and Medical Devices, Japan Agency for Medical Research; and Swiss Cancer Research grant. Summary Background Comparative assessment of treatment results in paediatric hepatoblastoma trials has been hampered by small patient numbers and the use of multiple disparate staging systems by the four major trial groups. To address this challenge, we formed a global coalition, the Children's Hepatic tumors International Collaboration (CHIC), with the aim of creating a common approach to staging and risk stratification in this rare cancer. Methods The CHIC steering committee—consisting of leadership from the four major cooperative trial groups (the International Childhood Liver Tumours Strategy Group, Children's Oncology Group, the German Society for Paediatric Oncology and Haematology, and the Japanese Study Group for Paediatric Liver Tumours)—created a shared international database that includes comprehensive data from 1605 children treated in eight multicentre hepatoblastoma trials over 25 years. Diagnostic factors found to be most prognostic on initial analysis were PRETreatment EXTent of disease (PRETEXT) group; age younger than 3 years, 3–7 years, and 8 years or older; α fetoprotein (AFP) concentration of 100 ng/mL or lower and 101–1000 ng/mL; and the PRETEXT annotation factors metastatic disease (M), macrovascular involvement of all hepatic veins (V) or portal bifurcation (P), contiguous extrahepatic tumour (E), multifocal tumour (F), and spontaneous rupture (R). We defined five clinically relevant backbone groups on the basis of established prognostic factors: PRETEXT I/II, PRETEXT III, PRETEXT IV, metastatic disease, and AFP concentration of 100 ng/mL or lower at diagnosis. We then carried the additional factors into a hierarchical backwards elimination multivariable analysis and used the results to create a new international staging system. Results Within each backbone group, we identified constellations of factors that were most predictive of outcome in that group. The robustness of candidate models was then interrogated using the bootstrapping procedure. Using the clinically established PRETEXT groups I, II, III, and IV as our stems, we created risk stratification trees based on 5 year event-free survival and clinical applicability. We defined and adopted four risk groups: very low, low, intermediate, and high. Interpretation We have created a unified global approach to risk stratification in children with hepatoblastoma on the basis of rigorous statistical interrogation of what is, to the best of our knowledge, the largest dataset ever assembled for this rare paediatric tumour. This achievement provides the structural framework for further collaboration and prospective international cooperative study, such as the Paediatric Hepatic International Tumour Trial (PHITT). Funding European Network for Cancer Research in Children and Adolescents, funded through the Framework Program 7 of the European Commission ( grant number 261474 ); Children's Oncology Group CureSearch grant contributed by the Hepatoblastoma Foundation; Practical Research for Innovative Cancer Control and Project Promoting Clinical Trials for Development of New Drugs and Medical Devices, Japan Agency for Medical Research; and Swiss Cancer Research grant. |
| Author | von Schweinitz, Dietrich Derosa, Marisa Krailo, Mark Schmid, Irene Malogolowkin, Marcio H Aronson, Daniel C Leuschner, Ivo Lopez-Terrada, Dolores Hiyama, Eiso Perilongo, Giorgio Watanabe, Kenichiro Rinaldi, Eugenia Alaggio, Rita Meyers, Rebecka L Ansari, Marc Saraceno, Davide Hishiki, Tomoro Häberle, Beate Rangaswami, Arun Feng, Yurong Czauderna, Piotr Yoshimura, Kenichi Maibach, Rudolf Tanaka, Yukichi |
| Author_xml | – sequence: 1 givenname: Rebecka L surname: Meyers fullname: Meyers, Rebecka L email: rebecka.meyers@imail2.org organization: University of Utah School of Medicine, Salt Lake City, UT, USA – sequence: 2 givenname: Rudolf surname: Maibach fullname: Maibach, Rudolf organization: International Breast Cancer Study Group Coordinating Center, Bern, Switzerland – sequence: 3 givenname: Eiso surname: Hiyama fullname: Hiyama, Eiso organization: Hiroshima University, Hiroshima, Japan – sequence: 4 givenname: Beate surname: Häberle fullname: Häberle, Beate organization: University of Munich, Munich, Germany – sequence: 5 givenname: Mark surname: Krailo fullname: Krailo, Mark organization: Children's Oncology Group, Monrovia, CA, USA – sequence: 6 givenname: Arun surname: Rangaswami fullname: Rangaswami, Arun organization: Stanford University, Palo Alto, CA, USA – sequence: 7 givenname: Daniel C surname: Aronson fullname: Aronson, Daniel C organization: Department of Paediatric Surgery, Noah's Ark Childrens' Hospital for Wales, University Hospital of Wales, Cardiff, UK – sequence: 8 givenname: Marcio H surname: Malogolowkin fullname: Malogolowkin, Marcio H organization: University of California Davis, Davis, CA, USA – sequence: 9 givenname: Giorgio surname: Perilongo fullname: Perilongo, Giorgio organization: University Hospital of Padua, Padua, Italy – sequence: 10 givenname: Dietrich surname: von Schweinitz fullname: von Schweinitz, Dietrich organization: University of Munich, Munich, Germany – sequence: 11 givenname: Marc surname: Ansari fullname: Ansari, Marc organization: Geneva University Hospital, Geneva, Switzerland – sequence: 12 givenname: Dolores surname: Lopez-Terrada fullname: Lopez-Terrada, Dolores organization: Baylor College of Medicine, Houston, TX, USA – sequence: 13 givenname: Yukichi surname: Tanaka fullname: Tanaka, Yukichi organization: Kanagawa Children's Medical Center, Yokohama, Japan – sequence: 14 givenname: Rita surname: Alaggio fullname: Alaggio, Rita organization: University Hospital of Padua, Padua, Italy – sequence: 15 givenname: Ivo surname: Leuschner fullname: Leuschner, Ivo organization: University of Kiel, Kiel, Germany – sequence: 16 givenname: Tomoro surname: Hishiki fullname: Hishiki, Tomoro organization: Department of Pediatric Surgery, Chiba University Hospital, Chiba, Japan – sequence: 17 givenname: Irene surname: Schmid fullname: Schmid, Irene organization: University of Munich, Munich, Germany – sequence: 18 givenname: Kenichiro surname: Watanabe fullname: Watanabe, Kenichiro organization: Shizuoka Children's Hospital, Shizuoka, Japan – sequence: 19 givenname: Kenichi surname: Yoshimura fullname: Yoshimura, Kenichi organization: Innovative Clinical Research Center (iCREK), Kanazawa University Hospital, Kanazawa, Japan – sequence: 20 givenname: Yurong surname: Feng fullname: Feng, Yurong organization: Children's Oncology Group, Monrovia, CA, USA – sequence: 21 givenname: Eugenia surname: Rinaldi fullname: Rinaldi, Eugenia organization: CINECA, Bologna, Italy – sequence: 22 givenname: Davide surname: Saraceno fullname: Saraceno, Davide organization: CINECA, Bologna, Italy – sequence: 23 givenname: Marisa surname: Derosa fullname: Derosa, Marisa organization: CINECA, Bologna, Italy – sequence: 24 givenname: Piotr surname: Czauderna fullname: Czauderna, Piotr organization: Medical University of Gdansk, Gdansk, Poland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27884679$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkstu1DAYhSNURC_wCCBLLCiLgJ3EsVNEERoBrVQJicvacpw_M2499mA7leYJeG2cpBQYCbWrxM45X_7LOcz2rLOQZU8JfkUwqV9_JRXDeYErekzqlyWmDc_5g-wgXVc5rTjfm95nyX52GMIlxoQRTB9l-wXjvKpZc5D9_KLDVR6il1H3GjoUolxqu0Taoo2ETsvotUIr2MjoWiNDdGt5giQa7KyXVppt0AH13q1RXAFarLTpPNgXAZ2NtmSPw9r5gM5tBG_TjUsmtHDGyNb56fw4e9hLE-DJzfMo-_7xw7fFWX7x-dP54v1FrmiDY15Bh3vWSICu7fuWy7IoGlp1qoES84aViteUsBJXDWt76JkivCVFmzphPZe4PMpOZ-5maNfQKbCpdSM2Xq-l3wontfj3i9UrsXTXgtYUFyVJgOMbgHc_BghRrHVQkFqx4IYgCKdNNVaC7yGtKlzUtOBJ-nxHeumGNCozAWlJcMnqpHr2d_G3Vf9eZxLQWaC8C8FDfyshWIyxEVNsxJgJkU5TbMT4-zc7PqXjtJc0A23udL-b3ZAWd63Bi6A0WJXS40FF0Tl9J-F0h6CMtlpJcwVbCH9mIUIh8AwZGaSeCCPg7f8B9yjgFyBmBzQ |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1002_jmri_28848 crossref_primary_10_1186_s13046_020_01598_8 crossref_primary_10_1002_jmri_28849 crossref_primary_10_3389_fped_2023_904730 crossref_primary_10_1055_s_0040_1722645 crossref_primary_10_1016_j_ejca_2022_06_013 crossref_primary_10_1007_s13304_024_01845_z crossref_primary_10_1016_j_actbio_2019_02_051 crossref_primary_10_1080_15384101_2022_2054635 crossref_primary_10_3390_children6010001 crossref_primary_10_1001_jamanetworkopen_2021_48013 crossref_primary_10_1002_pbc_27032 crossref_primary_10_1074_jbc_RA119_009979 crossref_primary_10_1007_s00761_021_00910_1 crossref_primary_10_1016_j_jflm_2020_102086 crossref_primary_10_1016_j_gene_2024_148292 crossref_primary_10_1016_j_eclinm_2024_102811 crossref_primary_10_1007_s00383_022_05362_1 crossref_primary_10_1186_s12957_021_02156_y crossref_primary_10_1177_1093526619875228 crossref_primary_10_3389_fcvm_2024_1419551 crossref_primary_10_1016_j_jpedsurg_2022_02_024 crossref_primary_10_1080_08880018_2020_1867266 crossref_primary_10_1186_s12887_025_05487_x crossref_primary_10_1007_s10555_019_09825_1 crossref_primary_10_1136_wjps_2020_000220 crossref_primary_10_1002_pbc_28350 crossref_primary_10_4240_wjgs_v16_i4_1066 crossref_primary_10_3390_children8111015 crossref_primary_10_1155_2022_2283541 crossref_primary_10_1053_j_sempedsurg_2019_04_014 crossref_primary_10_1007_s11912_022_01230_2 crossref_primary_10_1038_s41598_017_17665_8 crossref_primary_10_1590_0100_6991e_20223273 crossref_primary_10_1007_s00247_018_4078_z crossref_primary_10_1016_j_hpb_2025_03_007 crossref_primary_10_1016_j_surg_2020_12_035 crossref_primary_10_3390_cancers12082294 crossref_primary_10_1016_j_gene_2021_146050 crossref_primary_10_1002_cam4_3897 crossref_primary_10_3390_cells10123469 crossref_primary_10_1007_s00383_023_05533_8 crossref_primary_10_3390_cancers15153921 crossref_primary_10_1016_S1245_1789_21_44718_9 crossref_primary_10_1007_s00247_017_4050_3 crossref_primary_10_1016_j_omto_2020_06_007 crossref_primary_10_1007_s10147_018_1285_4 crossref_primary_10_1007_s40124_017_0141_8 crossref_primary_10_1016_j_prp_2024_155348 crossref_primary_10_3389_fmed_2020_00059 crossref_primary_10_1002_pbc_30766 crossref_primary_10_1038_s41467_022_32473_z crossref_primary_10_1111_petr_14641 crossref_primary_10_1007_s11901_017_0335_0 crossref_primary_10_1016_j_jhep_2023_05_031 crossref_primary_10_12998_wjcc_v7_i7_872 crossref_primary_10_1080_02656736_2021_1941310 crossref_primary_10_1002_pbc_27482 crossref_primary_10_3389_fgene_2022_858396 crossref_primary_10_1007_s10528_024_10764_y crossref_primary_10_1016_j_modpat_2023_100385 crossref_primary_10_7759_cureus_26494 crossref_primary_10_3389_fonc_2020_552079 crossref_primary_10_3390_diagnostics13233568 crossref_primary_10_1007_s00432_024_05858_4 crossref_primary_10_1186_s12929_017_0369_1 crossref_primary_10_1002_jgm_3182 crossref_primary_10_1111_jcmm_16124 crossref_primary_10_1371_journal_pone_0259503 crossref_primary_10_1016_j_epsc_2023_102578 crossref_primary_10_1007_s00432_024_05746_x crossref_primary_10_1186_s12885_021_09041_7 crossref_primary_10_1002_pbc_27479 crossref_primary_10_1177_1010428320977124 crossref_primary_10_3390_ijms241310858 crossref_primary_10_3390_biom14111394 crossref_primary_10_3390_cancers11030409 crossref_primary_10_3390_cancers11030407 crossref_primary_10_1016_j_prp_2024_155163 crossref_primary_10_1200_JCO_19_01067 crossref_primary_10_1007_s12029_020_00421_z crossref_primary_10_1097_MOT_0000000000000618 crossref_primary_10_6002_ect_PediatricSymp2022_L16 crossref_primary_10_1016_j_ejca_2020_09_026 crossref_primary_10_1111_apa_14952 crossref_primary_10_1016_j_ijpam_2020_11_001 crossref_primary_10_21682_2311_1267_2020_7_1_12_21 crossref_primary_10_1016_j_sempedsurg_2024_151384 crossref_primary_10_3390_cancers15215182 crossref_primary_10_15264_cpho_2020_27_1_43 crossref_primary_10_4103_ijc_IJC_824_18 crossref_primary_10_1038_s42003_023_04630_7 crossref_primary_10_3390_biom9120843 crossref_primary_10_1007_s00104_017_0568_z crossref_primary_10_1002_pbc_31389 crossref_primary_10_1111_petr_13581 crossref_primary_10_1016_j_clp_2020_11_005 crossref_primary_10_1016_j_humpath_2017_10_007 crossref_primary_10_1016_j_pedneo_2021_03_018 crossref_primary_10_3390_cancers12030720 crossref_primary_10_1002_jso_27038 crossref_primary_10_3389_fonc_2022_887210 crossref_primary_10_1002_pbc_28421 crossref_primary_10_1002_ccr3_7676 crossref_primary_10_1016_j_clp_2020_11_001 crossref_primary_10_3390_cancers14133083 crossref_primary_10_1016_j_jhep_2020_03_025 crossref_primary_10_18632_aging_204926 crossref_primary_10_3389_fonc_2021_741526 crossref_primary_10_1200_PO_19_00060 crossref_primary_10_2147_OTT_S228656 crossref_primary_10_3390_children9020234 crossref_primary_10_3390_cancers15020467 crossref_primary_10_1016_j_pathol_2023_11_007 crossref_primary_10_1016_j_canep_2020_101850 crossref_primary_10_1016_j_ejca_2024_113583 crossref_primary_10_1016_j_jpedsurg_2023_05_007 crossref_primary_10_1097_TP_0000000000003118 crossref_primary_10_1111_ajco_13421 crossref_primary_10_1002_ijc_33722 crossref_primary_10_1002_pbc_28641 crossref_primary_10_1007_s00383_022_05208_w crossref_primary_10_1016_j_jpedsurg_2023_05_001 crossref_primary_10_1002_pbc_27678 crossref_primary_10_3389_fpubh_2023_1049727 crossref_primary_10_1007_s00280_018_3625_5 crossref_primary_10_1007_s00330_021_08376_w crossref_primary_10_1007_s10147_019_01573_0 crossref_primary_10_3389_fgene_2019_00553 crossref_primary_10_3390_cancers14143524 crossref_primary_10_1016_j_jpedsurg_2017_08_031 crossref_primary_10_3390_ph14090845 crossref_primary_10_1111_ajt_16945 crossref_primary_10_1002_cam4_5300 crossref_primary_10_1007_s00383_022_05356_z crossref_primary_10_1007_s00247_018_4085_0 crossref_primary_10_32074_1591_951X_559 crossref_primary_10_1007_s00330_021_08047_w crossref_primary_10_1016_j_jflm_2022_102355 crossref_primary_10_1007_s00383_019_04473_6 crossref_primary_10_1002_pbc_29965 crossref_primary_10_1016_j_clinre_2021_101684 crossref_primary_10_1016_j_ajpath_2019_01_016 crossref_primary_10_1016_j_asjsur_2024_03_157 crossref_primary_10_1080_17843286_2024_2376304 crossref_primary_10_1186_s12887_021_02630_2 crossref_primary_10_18632_aging_203902 crossref_primary_10_1002_pbc_30019 crossref_primary_10_1002_hep_29779 crossref_primary_10_5582_bst_2023_01311 crossref_primary_10_3390_ijms25010427 crossref_primary_10_3389_fonc_2021_644994 crossref_primary_10_1002_pbc_28862 crossref_primary_10_1097_MPH_0000000000002918 crossref_primary_10_1002_cncr_34256 crossref_primary_10_1177_1093526620915987 crossref_primary_10_3389_fped_2024_1309693 crossref_primary_10_1016_j_ejso_2025_109694 crossref_primary_10_1080_15513815_2019_1652375 crossref_primary_10_1007_s00247_021_04989_x crossref_primary_10_1002_pbc_31339 crossref_primary_10_1111_liv_13687 crossref_primary_10_1002_pbc_31575 crossref_primary_10_3390_cancers11111693 crossref_primary_10_1002_pbc_29389 crossref_primary_10_1016_j_ymthe_2022_01_032 crossref_primary_10_1007_s00383_023_05465_3 crossref_primary_10_1016_j_pdpdt_2023_103790 crossref_primary_10_53730_ijhs_v6nS4_6103 crossref_primary_10_1002_hep_29672 crossref_primary_10_3389_fonc_2021_628531 crossref_primary_10_1002_cam4_6705 crossref_primary_10_3390_cancers11091258 crossref_primary_10_1016_j_ejcped_2024_100206 crossref_primary_10_1007_s13304_025_02140_1 crossref_primary_10_1111_petr_13409 crossref_primary_10_3390_cancers11121944 crossref_primary_10_3390_cancers14174196 crossref_primary_10_1016_j_jbior_2023_100997 crossref_primary_10_1007_s12519_023_00750_6 crossref_primary_10_1016_j_ejca_2018_10_013 crossref_primary_10_3390_cancers14112662 crossref_primary_10_1016_j_clinimag_2018_08_009 crossref_primary_10_1186_s13148_018_0462_7 crossref_primary_10_3390_cancers11091387 crossref_primary_10_1016_j_surg_2022_11_002 crossref_primary_10_1590_0100_6991e_20223273_en crossref_primary_10_3390_cancers15133355 crossref_primary_10_1016_j_jss_2021_06_077 crossref_primary_10_1007_s00247_018_4068_1 crossref_primary_10_3390_biomedicines10123091 crossref_primary_10_1016_j_jhep_2022_04_035 crossref_primary_10_1016_j_gene_2021_145834 crossref_primary_10_1016_j_sempedsurg_2019_150857 crossref_primary_10_1055_s_0045_1801884 crossref_primary_10_1111_ped_14134 crossref_primary_10_1016_j_heliyon_2022_e10301 crossref_primary_10_3389_fonc_2020_00556 crossref_primary_10_3389_fped_2025_1502761 crossref_primary_10_1016_j_path_2020_09_002 crossref_primary_10_1002_lt_24968 crossref_primary_10_1097_HC9_0000000000000435 crossref_primary_10_1097_RLU_0000000000004660 crossref_primary_10_1186_s12885_025_13592_4 crossref_primary_10_1097_MPG_0000000000003006 crossref_primary_10_1111_ped_13755 crossref_primary_10_3390_medicina57080819 crossref_primary_10_1007_s00261_024_04565_5 crossref_primary_10_1016_j_ijscr_2023_108931 crossref_primary_10_1016_j_jpedsurg_2024_07_025 crossref_primary_10_1002_bjs5_50297 crossref_primary_10_3390_cancers11050730 crossref_primary_10_1038_s41419_025_07502_6 crossref_primary_10_1007_s00761_021_00930_x crossref_primary_10_1016_j_pedneo_2020_03_012 crossref_primary_10_1200_JCO_2017_73_5654 crossref_primary_10_1016_j_soc_2020_11_006 crossref_primary_10_1097_MD_0000000000021174 crossref_primary_10_1016_j_ajpath_2020_03_011 crossref_primary_10_1002_pbc_30693 crossref_primary_10_3390_cancers11081215 crossref_primary_10_1007_s00383_024_05820_y crossref_primary_10_1016_j_heliyon_2024_e34510 crossref_primary_10_1016_j_clon_2019_03_044 crossref_primary_10_1038_s41467_021_25430_9 crossref_primary_10_1016_j_sempedsurg_2023_151340 crossref_primary_10_3390_cancers16010012 |
| Cites_doi | 10.1200/JCO.2005.07.145 10.1016/j.ejca.2011.12.011 10.3109/08880019809167228 10.1200/JCO.2000.18.14.2665 10.1016/S0895-4356(01)00341-9 10.1007/s00247-006-0361-5 10.1200/JCO.2009.22.4857 10.1002/(SICI)1097-0215(19971219)74:6<593::AID-IJC6>3.0.CO;2-P 10.1002/pbc.24217 10.1016/j.ejca.2015.09.023 10.1200/JCO.2014.58.3369 10.1200/JCO.2005.02.6013 10.1053/jpsu.2002.32886 10.1093/bioinformatics/btg419 10.1002/cncr.24667 10.1200/JCO.2010.29.3837 10.1056/NEJMoa0810613 10.1002/cncr.10632 10.1053/j.sempedsurg.2011.10.011 10.1016/j.ejca.2003.06.003 10.1007/s00383-010-2708-0 10.2741/e395 10.1097/MOP.0000000000000046 10.1097/MOP.0000000000000042 10.1002/pbc.22088 10.1002/pbc.24215 |
| ContentType | Journal Article |
| Copyright | 2017 Elsevier Ltd Elsevier Ltd Copyright © 2017 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Jan 01, 2017 |
| Copyright_xml | – notice: 2017 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2017 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Jan 01, 2017 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 0TZ 3V. 7RV 7TO 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1016/S1470-2045(16)30598-8 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Pharma and Biotech Premium PRO ProQuest Central (Corporate) Nursing & Allied Health Database (Proquest) Oncogenes and Growth Factors Abstracts Health & Medical Collection (Proquest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Proquest Public Health Database Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Pharma and Biotech Premium PRO Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Oncogenes and Growth Factors Abstracts MEDLINE - Academic Pharma and Biotech Premium PRO |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-5488 |
| EndPage | 131 |
| ExternalDocumentID | PMC5650231 4293357521 27884679 10_1016_S1470_2045_16_30598_8 S1470204516305988 1_s2_0_S1470204516305988 |
| Genre | Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation | European Network for Cancer Research in Children and Adolescents, funded through the Framework Program 7 of the European Commission (grant number 261474); Children's Oncology Group CureSearch grant contributed by the Hepatoblastoma Foundation; Practical Research for Innovative Cancer Control and Project Promoting Clinical Trials for Development of New Drugs and Medical Devices, Japan Agency for Medical Research; and Swiss Cancer Research grant. |
| GrantInformation_xml | – fundername: Framework Program 7 of the European Commission grantid: grant number 261474 – fundername: NCI NIH HHS grantid: U10 CA180899 |
| GroupedDBID | --- --K --M -RU .1- .55 .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4CK 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABMAC ABMZM ABUWG ABWVN ACGFS ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEVXI AFKRA AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OC~ OO- OZT P-8 P-9 P2P PCD PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO R2- ROL RPZ SDG SEL SES SPCBC SSH SSZ T5K TLN UKHRP UV1 WOW X7M XBR Z5R 3V. AACTN AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF ABLVK ABYKQ AHPSJ AJBFU ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 0TZ 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 ACLOT ~HD 5PM |
| ID | FETCH-LOGICAL-c590t-4ed0f79aeedbffb8a322954dc9e308973c8651730497bfef7c18b12baed7f8a03 |
| IEDL.DBID | 8C1 |
| ISSN | 1470-2045 1474-5488 |
| IngestDate | Thu Aug 21 14:03:03 EDT 2025 Sat Sep 27 22:26:53 EDT 2025 Sun Sep 28 00:48:24 EDT 2025 Fri Jul 25 06:02:30 EDT 2025 Wed Feb 19 02:41:34 EST 2025 Tue Jul 01 04:04:52 EDT 2025 Thu Apr 24 22:55:21 EDT 2025 Fri Feb 23 02:31:14 EST 2024 Tue Feb 25 20:02:54 EST 2025 Tue Aug 26 19:22:07 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Copyright © 2017 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c590t-4ed0f79aeedbffb8a322954dc9e308973c8651730497bfef7c18b12baed7f8a03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 These authors contributed equally |
| PMID | 27884679 |
| PQID | 1855310376 |
| PQPubID | 46089 |
| PageCount | 10 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5650231 proquest_miscellaneous_1859489730 proquest_miscellaneous_1844026528 proquest_journals_1855310376 pubmed_primary_27884679 crossref_primary_10_1016_S1470_2045_16_30598_8 crossref_citationtrail_10_1016_S1470_2045_16_30598_8 elsevier_sciencedirect_doi_10_1016_S1470_2045_16_30598_8 elsevier_clinicalkeyesjournals_1_s2_0_S1470204516305988 elsevier_clinicalkey_doi_10_1016_S1470_2045_16_30598_8 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2017-01-01 |
| PublicationDateYYYYMMDD | 2017-01-01 |
| PublicationDate_xml | – month: 01 year: 2017 text: 2017-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The lancet oncology |
| PublicationTitleAlternate | Lancet Oncol |
| PublicationYear | 2017 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Hishiki, Matsunaga, Sasaki (bib20) 2011; 27 Meyers, Rowland, Krailo (bib7) 2009; 53 Blohm, Vesterling-Hörner, Calaminus, Göbel (bib23) 1998; 15 Steyerberg, Harrell, Borsboom, Eijkemans, Vergouwe, Habbema (bib24) 2001; 54 Perilongo, Shafford, Maibach (bib11) 2004; 40 von Schweinitz, Hecker, Schmidt-von-Arndt (bib17) 1997; 74 Zsiros, Maibach, Shafford (bib13) 2010; 28 Frazier, Hale, Rodriguez-Galindo (bib26) 2014; 33 Haeberle, von Schweinitz (bib18) 2012; 1 Braga-Neto, Dougherty (bib25) 2004; 20 Perilongo, Malogolowkin, Feusner (bib3) 2012; 59 Sasaki, Matsunaga, Iwafuchi (bib19) 2002; 37 Perilongo, Maibach, Shafford (bib12) 2009; 361 Lopez-Terrada, Alaggio, DeDavila (bib28) 2014; 26 Spector, Birch (bib1) 2012; 59 Maibach, Roebuck, Brugieres (bib8) 2012; 48 Malogolowkin, Katzenstein, Meyers (bib27) 2011; 29 Meyers, Tiao, de ville de (bib4) 2014; 26 von Schweinitz (bib9) 2012; 21 Katzenstein, Chang, Krailo (bib16) 2009; 115 Aronson, Schnater, Staalman (bib6) 2005; 23 Czauderna, Haeberle, Hiyama (bib10) 2016; 52 Ortega, Douglass, Feusner (bib14) 2000; 18 Malogolowkin, Katzenstein, Krailo (bib15) 2006; 24 Pritchard, Plaschkes, Shafford (bib21) 1992; 20 Roebuck, Aronson, Clapuyt (bib22) 2007; 37 Fuchs, Rydzynski, von Schweinitz (bib5) 2002; 95 Czauderna, Lopez-Terrada, Hiyama (bib2) 2014; 26 Czauderna (10.1016/S1470-2045(16)30598-8_bib10) 2016; 52 Sasaki (10.1016/S1470-2045(16)30598-8_bib19) 2002; 37 Czauderna (10.1016/S1470-2045(16)30598-8_bib2) 2014; 26 Spector (10.1016/S1470-2045(16)30598-8_bib1) 2012; 59 Frazier (10.1016/S1470-2045(16)30598-8_bib26) 2014; 33 Aronson (10.1016/S1470-2045(16)30598-8_bib6) 2005; 23 Steyerberg (10.1016/S1470-2045(16)30598-8_bib24) 2001; 54 Perilongo (10.1016/S1470-2045(16)30598-8_bib11) 2004; 40 Pritchard (10.1016/S1470-2045(16)30598-8_bib21) 1992; 20 Meyers (10.1016/S1470-2045(16)30598-8_bib7) 2009; 53 Maibach (10.1016/S1470-2045(16)30598-8_bib8) 2012; 48 Perilongo (10.1016/S1470-2045(16)30598-8_bib12) 2009; 361 Meyers (10.1016/S1470-2045(16)30598-8_bib4) 2014; 26 Fuchs (10.1016/S1470-2045(16)30598-8_bib5) 2002; 95 Malogolowkin (10.1016/S1470-2045(16)30598-8_bib15) 2006; 24 Haeberle (10.1016/S1470-2045(16)30598-8_bib18) 2012; 1 Lopez-Terrada (10.1016/S1470-2045(16)30598-8_bib28) 2014; 26 Hishiki (10.1016/S1470-2045(16)30598-8_bib20) 2011; 27 von Schweinitz (10.1016/S1470-2045(16)30598-8_bib9) 2012; 21 Perilongo (10.1016/S1470-2045(16)30598-8_bib3) 2012; 59 Roebuck (10.1016/S1470-2045(16)30598-8_bib22) 2007; 37 Braga-Neto (10.1016/S1470-2045(16)30598-8_bib25) 2004; 20 Ortega (10.1016/S1470-2045(16)30598-8_bib14) 2000; 18 Blohm (10.1016/S1470-2045(16)30598-8_bib23) 1998; 15 Malogolowkin (10.1016/S1470-2045(16)30598-8_bib27) 2011; 29 Katzenstein (10.1016/S1470-2045(16)30598-8_bib16) 2009; 115 Zsiros (10.1016/S1470-2045(16)30598-8_bib13) 2010; 28 von Schweinitz (10.1016/S1470-2045(16)30598-8_bib17) 1997; 74 14746860 - Eur J Cancer. 2004 Feb;40(3):411-21 19588519 - Pediatr Blood Cancer. 2009 Dec;53(6):1016-22 19846851 - N Engl J Med. 2009 Oct 22;361(17):1662-70 12115331 - Cancer. 2002 Jul 1;95(1):172-82 26655560 - Eur J Cancer. 2016 Jan;52:92-101 12037748 - J Pediatr Surg. 2002 Jun;37(6):851-6 9592840 - Pediatr Hematol Oncol. 1998 Mar-Apr;15(2):135-42 25452439 - J Clin Oncol. 2015 Jan 10;33(2):195-201 27884678 - Lancet Oncol. 2017 Jan;18(1):13-15 15718322 - J Clin Oncol. 2005 Feb 20;23(6):1245-52 10894865 - J Clin Oncol. 2000 Jul;18(14):2665-75 22244829 - Eur J Cancer. 2012 Jul;48(10):1543-9 16782927 - J Clin Oncol. 2006 Jun 20;24(18):2879-84 17186233 - Pediatr Radiol. 2007 Feb;37(2):123-32; quiz 249-50 22248967 - Semin Pediatr Surg. 2012 Feb;21(1):21-30 24322718 - Curr Opin Pediatr. 2014 Feb;26(1):19-28 9421354 - Int J Cancer. 1997 Dec 19;74(6):593-9 14960464 - Bioinformatics. 2004 Feb 12;20(3):374-80 22692949 - Pediatr Blood Cancer. 2012 Nov;59(5):776-9 11470385 - J Clin Epidemiol. 2001 Aug;54(8):774-81 20922397 - Pediatr Surg Int. 2011 Jan;27(1):1-8 20406943 - J Clin Oncol. 2010 May 20;28(15):2584-90 24362406 - Curr Opin Pediatr. 2014 Feb;26(1):29-36 22678761 - Pediatr Blood Cancer. 2012 Nov;59(5):818-21 22201890 - Front Biosci (Elite Ed). 2012 Jan 01;4:493-8 19813275 - Cancer. 2009 Dec 15;115(24):5828-35 21768450 - J Clin Oncol. 2011 Aug 20;29(24):3301-6 |
| References_xml | – volume: 74 start-page: 593 year: 1997 end-page: 599 ident: bib17 article-title: Prognostic factors and staging systems in childhood hepatoblastoma publication-title: Int J Cancer – volume: 95 start-page: 172 year: 2002 end-page: 182 ident: bib5 article-title: Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB94 publication-title: Cancer – volume: 48 start-page: 1543 year: 2012 end-page: 1549 ident: bib8 article-title: Prognostic stratification for children with hepatoblastoma: the SIOPEL experience publication-title: Eur J Cancer – volume: 20 start-page: 389 year: 1992 ident: bib21 article-title: SIOPEL I: the first SIOP hepatoblastoma (hepatoblastoma) and hepatocellular carcinoma (HCC) study. Preliminary results publication-title: Med Ped Oncol – volume: 29 start-page: 3301 year: 2011 end-page: 3306 ident: bib27 article-title: Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children's Oncology Group publication-title: J Clin Oncol – volume: 23 start-page: 1245 year: 2005 end-page: 1252 ident: bib6 article-title: Predictive value of the pre-treatment extent of disease system in hepatoblastoma: results from the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study publication-title: J Clin Oncol – volume: 59 start-page: 818 year: 2012 end-page: 821 ident: bib3 article-title: Hepatoblastoma clinical research: lessons learned and future challenges publication-title: Pediatr Blood Cancer – volume: 115 start-page: 5828 year: 2009 end-page: 5835 ident: bib16 article-title: Amifostine does not prevent platinum-induced hearing loss associated with treatment of children with hepatoblastoma; a report of the Intergroup Hepatoblastoma Study P9645 as part of Children's Oncology Group publication-title: Cancer – volume: 40 start-page: 411 year: 2004 end-page: 421 ident: bib11 article-title: Risk adapted treatment for childhood hepatoblastoma: final report of the second study of the Internal Society Of Pediatric Oncology, SIOPEL 2 publication-title: Eur J Cancer – volume: 26 start-page: 19 year: 2014 end-page: 28 ident: bib28 article-title: Towards an international paediatric liver tumour consensus classification: proceedings of the Los Angeles COG International Pathology Paediatric Liver Tumours Symposium publication-title: Mod Pathol – volume: 24 start-page: 2879 year: 2006 end-page: 2884 ident: bib15 article-title: Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma publication-title: J Clin Oncol – volume: 28 start-page: 2584 year: 2010 end-page: 2590 ident: bib13 article-title: Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study publication-title: J Clin Oncol – volume: 15 start-page: 135 year: 1998 end-page: 142 ident: bib23 article-title: Alpha publication-title: Pediatr Hematol Oncol – volume: 37 start-page: 851 year: 2002 end-page: 856 ident: bib19 article-title: Outcome of hepatoblastoma treatment with JPLT-1 Protocol-1: a report from the Japanese study group for pediatric liver tumor publication-title: J Pediatr Surg – volume: 18 start-page: 2665 year: 2000 end-page: 2675 ident: bib14 article-title: Randomized comparison of cisplatin/vincristin/5-fluorouracil and cisplatin/doxorubicin for the treatment of pediatric hepatoblastoma (HB): a report from the Children's Cancer Group and the Pediatric Oncology Group publication-title: J Clin Oncol – volume: 361 start-page: 1662 year: 2009 end-page: 1670 ident: bib12 article-title: Cisplatin versus cisplatin plus doxorubicin for standard risk hepatoblastoma publication-title: N Engl J Med – volume: 59 start-page: 776 year: 2012 end-page: 779 ident: bib1 article-title: The epidemiology of hepatoblastoma publication-title: Pediatr Blood Cancer – volume: 26 start-page: 29 year: 2014 end-page: 36 ident: bib4 article-title: Hepatoblastoma state of the art: PRETEXT, surgical resection guidelines and the role of liver transplantation publication-title: Curr Opin Pediatr – volume: 54 start-page: 774 year: 2001 end-page: 781 ident: bib24 article-title: Internal validation of predictive models: efficiency of some procedures for logistic regression analysis publication-title: J Clin Epidemiol – volume: 21 start-page: 21 year: 2012 end-page: 30 ident: bib9 article-title: Hepatoblastoma: recent developments in research and treatment publication-title: Semin Pediatr Surg – volume: 27 start-page: 1 year: 2011 end-page: 8 ident: bib20 article-title: Outcome of hepatoblastoma treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT publication-title: Pediatr Surg Int – volume: 33 start-page: 195 year: 2014 end-page: 201 ident: bib26 article-title: Revised risk classification for paediatric extracranial germ cell tumours based on 25 years of clinical trial data from the United Kingdom and United States publication-title: J Clin Oncol – volume: 1 start-page: 493 year: 2012 end-page: 498 ident: bib18 article-title: Treatment of hepatoblastoma in German cooperative pediatric liver tumor studies publication-title: Front Biosci – volume: 20 start-page: 374 year: 2004 end-page: 380 ident: bib25 article-title: Is cross validation valid for small-sample microarray classification? publication-title: Bioinformatics – volume: 52 start-page: 92 year: 2016 end-page: 101 ident: bib10 article-title: The Children's Hepatic tumors International Collaboration (CHIC): novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model publication-title: Eur J Cancer – volume: 26 start-page: 19 year: 2014 end-page: 28 ident: bib2 article-title: Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy publication-title: Curr Opin Pediatr – volume: 37 start-page: 123 year: 2007 end-page: 132 ident: bib22 article-title: 2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group publication-title: Pediatr Radiol – volume: 53 start-page: 1016 year: 2009 end-page: 1022 ident: bib7 article-title: Pretreatment prognostic factors in hepatoblastoma: a report of the Children's Oncology Group publication-title: Pediatr Blood Cancer – volume: 23 start-page: 1245 year: 2005 ident: 10.1016/S1470-2045(16)30598-8_bib6 article-title: Predictive value of the pre-treatment extent of disease system in hepatoblastoma: results from the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study publication-title: J Clin Oncol doi: 10.1200/JCO.2005.07.145 – volume: 20 start-page: 389 year: 1992 ident: 10.1016/S1470-2045(16)30598-8_bib21 article-title: SIOPEL I: the first SIOP hepatoblastoma (hepatoblastoma) and hepatocellular carcinoma (HCC) study. Preliminary results publication-title: Med Ped Oncol – volume: 48 start-page: 1543 year: 2012 ident: 10.1016/S1470-2045(16)30598-8_bib8 article-title: Prognostic stratification for children with hepatoblastoma: the SIOPEL experience publication-title: Eur J Cancer doi: 10.1016/j.ejca.2011.12.011 – volume: 15 start-page: 135 year: 1998 ident: 10.1016/S1470-2045(16)30598-8_bib23 article-title: Alpha1-fetoprotein (AFP) reference values in infants up to 2 years of age publication-title: Pediatr Hematol Oncol doi: 10.3109/08880019809167228 – volume: 18 start-page: 2665 year: 2000 ident: 10.1016/S1470-2045(16)30598-8_bib14 article-title: Randomized comparison of cisplatin/vincristin/5-fluorouracil and cisplatin/doxorubicin for the treatment of pediatric hepatoblastoma (HB): a report from the Children's Cancer Group and the Pediatric Oncology Group publication-title: J Clin Oncol doi: 10.1200/JCO.2000.18.14.2665 – volume: 54 start-page: 774 year: 2001 ident: 10.1016/S1470-2045(16)30598-8_bib24 article-title: Internal validation of predictive models: efficiency of some procedures for logistic regression analysis publication-title: J Clin Epidemiol doi: 10.1016/S0895-4356(01)00341-9 – volume: 37 start-page: 123 year: 2007 ident: 10.1016/S1470-2045(16)30598-8_bib22 article-title: 2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group publication-title: Pediatr Radiol doi: 10.1007/s00247-006-0361-5 – volume: 28 start-page: 2584 year: 2010 ident: 10.1016/S1470-2045(16)30598-8_bib13 article-title: Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study publication-title: J Clin Oncol doi: 10.1200/JCO.2009.22.4857 – volume: 74 start-page: 593 year: 1997 ident: 10.1016/S1470-2045(16)30598-8_bib17 article-title: Prognostic factors and staging systems in childhood hepatoblastoma publication-title: Int J Cancer doi: 10.1002/(SICI)1097-0215(19971219)74:6<593::AID-IJC6>3.0.CO;2-P – volume: 59 start-page: 818 year: 2012 ident: 10.1016/S1470-2045(16)30598-8_bib3 article-title: Hepatoblastoma clinical research: lessons learned and future challenges publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.24217 – volume: 52 start-page: 92 year: 2016 ident: 10.1016/S1470-2045(16)30598-8_bib10 article-title: The Children's Hepatic tumors International Collaboration (CHIC): novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model publication-title: Eur J Cancer doi: 10.1016/j.ejca.2015.09.023 – volume: 33 start-page: 195 year: 2014 ident: 10.1016/S1470-2045(16)30598-8_bib26 article-title: Revised risk classification for paediatric extracranial germ cell tumours based on 25 years of clinical trial data from the United Kingdom and United States publication-title: J Clin Oncol doi: 10.1200/JCO.2014.58.3369 – volume: 24 start-page: 2879 year: 2006 ident: 10.1016/S1470-2045(16)30598-8_bib15 article-title: Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma publication-title: J Clin Oncol doi: 10.1200/JCO.2005.02.6013 – volume: 37 start-page: 851 year: 2002 ident: 10.1016/S1470-2045(16)30598-8_bib19 article-title: Outcome of hepatoblastoma treatment with JPLT-1 Protocol-1: a report from the Japanese study group for pediatric liver tumor publication-title: J Pediatr Surg doi: 10.1053/jpsu.2002.32886 – volume: 20 start-page: 374 year: 2004 ident: 10.1016/S1470-2045(16)30598-8_bib25 article-title: Is cross validation valid for small-sample microarray classification? publication-title: Bioinformatics doi: 10.1093/bioinformatics/btg419 – volume: 115 start-page: 5828 year: 2009 ident: 10.1016/S1470-2045(16)30598-8_bib16 article-title: Amifostine does not prevent platinum-induced hearing loss associated with treatment of children with hepatoblastoma; a report of the Intergroup Hepatoblastoma Study P9645 as part of Children's Oncology Group publication-title: Cancer doi: 10.1002/cncr.24667 – volume: 29 start-page: 3301 year: 2011 ident: 10.1016/S1470-2045(16)30598-8_bib27 article-title: Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children's Oncology Group publication-title: J Clin Oncol doi: 10.1200/JCO.2010.29.3837 – volume: 361 start-page: 1662 year: 2009 ident: 10.1016/S1470-2045(16)30598-8_bib12 article-title: Cisplatin versus cisplatin plus doxorubicin for standard risk hepatoblastoma publication-title: N Engl J Med doi: 10.1056/NEJMoa0810613 – volume: 95 start-page: 172 year: 2002 ident: 10.1016/S1470-2045(16)30598-8_bib5 article-title: Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB94 publication-title: Cancer doi: 10.1002/cncr.10632 – volume: 21 start-page: 21 year: 2012 ident: 10.1016/S1470-2045(16)30598-8_bib9 article-title: Hepatoblastoma: recent developments in research and treatment publication-title: Semin Pediatr Surg doi: 10.1053/j.sempedsurg.2011.10.011 – volume: 40 start-page: 411 year: 2004 ident: 10.1016/S1470-2045(16)30598-8_bib11 article-title: Risk adapted treatment for childhood hepatoblastoma: final report of the second study of the Internal Society Of Pediatric Oncology, SIOPEL 2 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2003.06.003 – volume: 27 start-page: 1 year: 2011 ident: 10.1016/S1470-2045(16)30598-8_bib20 article-title: Outcome of hepatoblastoma treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT publication-title: Pediatr Surg Int doi: 10.1007/s00383-010-2708-0 – volume: 1 start-page: 493 year: 2012 ident: 10.1016/S1470-2045(16)30598-8_bib18 article-title: Treatment of hepatoblastoma in German cooperative pediatric liver tumor studies publication-title: Front Biosci doi: 10.2741/e395 – volume: 26 start-page: 19 year: 2014 ident: 10.1016/S1470-2045(16)30598-8_bib2 article-title: Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy publication-title: Curr Opin Pediatr doi: 10.1097/MOP.0000000000000046 – volume: 26 start-page: 29 year: 2014 ident: 10.1016/S1470-2045(16)30598-8_bib4 article-title: Hepatoblastoma state of the art: PRETEXT, surgical resection guidelines and the role of liver transplantation publication-title: Curr Opin Pediatr doi: 10.1097/MOP.0000000000000042 – volume: 26 start-page: 19 year: 2014 ident: 10.1016/S1470-2045(16)30598-8_bib28 article-title: Towards an international paediatric liver tumour consensus classification: proceedings of the Los Angeles COG International Pathology Paediatric Liver Tumours Symposium publication-title: Mod Pathol – volume: 53 start-page: 1016 year: 2009 ident: 10.1016/S1470-2045(16)30598-8_bib7 article-title: Pretreatment prognostic factors in hepatoblastoma: a report of the Children's Oncology Group publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.22088 – volume: 59 start-page: 776 year: 2012 ident: 10.1016/S1470-2045(16)30598-8_bib1 article-title: The epidemiology of hepatoblastoma publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.24215 – reference: 19846851 - N Engl J Med. 2009 Oct 22;361(17):1662-70 – reference: 11470385 - J Clin Epidemiol. 2001 Aug;54(8):774-81 – reference: 22678761 - Pediatr Blood Cancer. 2012 Nov;59(5):818-21 – reference: 10894865 - J Clin Oncol. 2000 Jul;18(14):2665-75 – reference: 22692949 - Pediatr Blood Cancer. 2012 Nov;59(5):776-9 – reference: 20922397 - Pediatr Surg Int. 2011 Jan;27(1):1-8 – reference: 17186233 - Pediatr Radiol. 2007 Feb;37(2):123-32; quiz 249-50 – reference: 9592840 - Pediatr Hematol Oncol. 1998 Mar-Apr;15(2):135-42 – reference: 12037748 - J Pediatr Surg. 2002 Jun;37(6):851-6 – reference: 26655560 - Eur J Cancer. 2016 Jan;52:92-101 – reference: 15718322 - J Clin Oncol. 2005 Feb 20;23(6):1245-52 – reference: 9421354 - Int J Cancer. 1997 Dec 19;74(6):593-9 – reference: 22248967 - Semin Pediatr Surg. 2012 Feb;21(1):21-30 – reference: 19813275 - Cancer. 2009 Dec 15;115(24):5828-35 – reference: 20406943 - J Clin Oncol. 2010 May 20;28(15):2584-90 – reference: 22244829 - Eur J Cancer. 2012 Jul;48(10):1543-9 – reference: 24362406 - Curr Opin Pediatr. 2014 Feb;26(1):29-36 – reference: 16782927 - J Clin Oncol. 2006 Jun 20;24(18):2879-84 – reference: 21768450 - J Clin Oncol. 2011 Aug 20;29(24):3301-6 – reference: 24322718 - Curr Opin Pediatr. 2014 Feb;26(1):19-28 – reference: 14960464 - Bioinformatics. 2004 Feb 12;20(3):374-80 – reference: 12115331 - Cancer. 2002 Jul 1;95(1):172-82 – reference: 27884678 - Lancet Oncol. 2017 Jan;18(1):13-15 – reference: 14746860 - Eur J Cancer. 2004 Feb;40(3):411-21 – reference: 22201890 - Front Biosci (Elite Ed). 2012 Jan 01;4:493-8 – reference: 19588519 - Pediatr Blood Cancer. 2009 Dec;53(6):1016-22 – reference: 25452439 - J Clin Oncol. 2015 Jan 10;33(2):195-201 |
| SSID | ssj0017105 |
| Score | 2.6434925 |
| Snippet | Comparative assessment of treatment results in paediatric hepatoblastoma trials has been hampered by small patient numbers and the use of multiple disparate... Summary Background Comparative assessment of treatment results in paediatric hepatoblastoma trials has been hampered by small patient numbers and the use of... Background Comparative assessment of treatment results in paediatric hepatoblastoma trials has been hampered by small patient numbers and the use of multiple... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 122 |
| SubjectTerms | Adolescent Age alpha-Fetoproteins - metabolism Child Child, Preschool Children & youth Collaboration Combined Modality Therapy Cooperative Behavior Databases, Factual Datasets Decades Female Follow-Up Studies Hematology, Oncology and Palliative Medicine Hepatoblastoma - secondary Hepatoblastoma - therapy Histology Humans Infant Infant, Newborn International Agencies Japan Liver Neoplasms - pathology Liver Neoplasms - therapy Lymphatic Metastasis Male Medical prognosis Metastasis Neoplasm Staging - standards Patients Prognosis Prospective Studies Risk Factors Studies Survival Rate Tumors |
| Title | Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1470204516305988 https://www.clinicalkey.es/playcontent/1-s2.0-S1470204516305988 https://dx.doi.org/10.1016/S1470-2045(16)30598-8 https://www.ncbi.nlm.nih.gov/pubmed/27884679 https://www.proquest.com/docview/1855310376 https://www.proquest.com/docview/1844026528 https://www.proquest.com/docview/1859489730 https://pubmed.ncbi.nlm.nih.gov/PMC5650231 |
| Volume | 18 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZoKyEuiHcXyspISMDBNI6d2OGCYNVqhdQKFSrtzXKcWF1Bk6XJ_gb-NjOJk3Z5tBwTz6c8Zuz5_JgZQl66zHqhuGMyF5JJ4Upm08wyYBbWA01KIo6xw0fH6fxUfloki7Dg1oRjlcOY2A3URe1wjXwf_EqCNbFU-n71g2HVKNxdDSU0tsgOxoDi5EvPxiMeXPVHGLlUEcO065cRPPtfxpuvefoGjD7TTP_LN_3JPX8_QnnFJx3eI3cDmaQfeu3fJ7fK6gG5fRS2yx-SnyfL5hvrM-N64JoUqCAWJaLLiq7sUKSDnoFLgn4NPLqtz-07aum66uVtSFlCMQqFAleksxD8_aqhc4QBvF2f1xcN3VhbpLOr9vWInB4efJ3NWai8wFySRS2TZRF5lVlwoLn3ubYCq37LwmWliHSmhNNpwhVu0ancl145rnMe5_Dmymsbicdku6qrcpdQqwvpuAUBLyS0aSe9KnzBizy2WvAJkcM_Ny6kJcfqGN_NeP4MVWVQVQauOlUZPSFvR9iqz8txEyAdFGqGoFMYJg14jpuA6m_AsgmdvTHcNLGJejSCgeIiFJB6RAY-0_OU_3no3mBz5vI5YxeYkBdjMwwHuMdjq7Jeo4yUMK1OYn2dDOboAS1GE_KkN-PxH8ZKIyPN4Ks3DHwUwHTkmy3V8qxLSw5TA0wm-PT6V39G7sTIjLpVrD2y3V6sy-fA69p8SrbUQk27LjwlOx8Pjj-f_AIGPUxP |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1tb9MwELZGJwFfEO8UBhgJBHzwFidO7CBNCMqmjq0VGpu0b8ZJbK2CpWVphfgF_Ct-G3eNk628bHzZx9T3JGnOvnv8cneEPM1T4yLJcyaySDAR5ZaZJDUMmIVxQJPigGPs8GCY9PfF-4P4YIn8bGJh8FhlYxPnhroY57hGvgZ-JcaaWDJ5PfnKsGoU7q42JTSML61QrM9TjPnAjm37_RtM4ar1rXeg72dhuLmx1-szX2WA5XEaTJmwReBkasBZZM5lykRY4VoUeWqjQKUyylUSc4nbUTJz1smcq4yHmbGFdMoEEdz3ElkWuIDSIctvN4Yfdtt9DFkfouRCBgwTv5_EEK19bH98wZOXMOxSxdS_vOOf7Pf3Q5ynvOLmdXLN01n6pu5_N8iSLW-SywO_YX-L_NgdVZ9ZnZvXAdulQEaxLBIdlXRimjIh9BCcIlgWYPLT8ZF5RQ2dlbW88UlTKMbBUGCrtOfDz59XtI8wgE9nR-Pjii6sbtLe6R5-m-xfiFbukE45Lu09Qo0qRM4NCLhIQJvKhZOFK3iRhUZFvEtE88117hOjY32OL7o9AYeq0qgqDVdzVWnVJastbFJnBjkPkDQK1U3YKxhqDb7rPKD8G9BW3txUmusq1EGNRjCQbIQCUrVIz6hqpvQ_D11p-pw-eU47CLvkSdsMBgl3mUxpxzOUEQIm9nGozpLBLEGgxaBL7tbduP2GoVTIiVP41wsdvBXAhOiLLeXocJ4YHSYnmM7w_tmv_phc6e8NdvTO1nD7AbkaIk-br6mtkM70eGYfAsucZo_8UKbk00Vbj1-ssI7r |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1tb9MwELbGJk18QbxTGGAkEPDBa16c2EGaEHSrOsaqaTBp34zj2FoFS8vSCvEL-G_8Ku4aJ1t52fiyj6n9JGnOvnvs890R8tRk2sUiNIznMWc8NpbpNNMMmIV2QJOSIMTY4d1hOjjg7w6TwyXys4mFwWOVjU6cK-pibHCPvAt2JcGaWCLtOn8sYm-z_3rylWEFKfS0NuU0tC-zUGzM0435II8d-_0bLOeqje1NkP2zKOpvfewNmK84wEySBVPGbRE4kWkwHLlzudQxVrvmhclsHMhMxEamSSjQNSVyZ50woczDKNe2EE7qIIb7XiErAqw-LARX3m4N9_Zbn4aoD1SGXAQMk8CfxhN1P7Q_vgjTlzAFM8nkvyzln0z49wOdZyxk_zq55qktfVOPxRtkyZY3yequd97fIj_2R9VnVufpdcB8KRBTLJFERyWd6KZkCD0CAwlaBlj9dHysX1FNZ2XdX_sEKhRjYigwV9rzoejPKzpAGMCns-PxSUUXdjpp7-xov00OLkUqd8hyOS7tPUK1LLgJNXRwMYc2abgThSvCIo-0jMMO4c03V8YnScdaHV9UexoORaVQVAqu5qJSskPWW9ikzhJyESBtBKqaEFhQ2grs2EVA8TegrbzqqVSoqkgFNRrBQLgRCkjZIj27qlnT_zx0rRlz6vQ57YTskCdtMygn9Djp0o5n2IdzWOQnkTyvD2YMAikGHXK3HsbtN4yERH6cwb9eGOBtB0yOvthSjo7mSdJhoYKpDe-f_-qPySpoEfV-e7jzgFyNkLLNt9fWyPL0ZGYfAuGc5o_8TKbk02Urj1-3aJMv |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk-stratified+staging+in+paediatric+hepatoblastoma%3A+a+unified+analysis+from+the+Children%27s+Hepatic+tumors+International+Collaboration&rft.jtitle=The+lancet+oncology&rft.au=Meyers%2C+Rebecka+L&rft.au=Maibach%2C+Rudolf&rft.au=Hiyama%2C+Eiso&rft.au=H%C3%A4berle%2C+Beate&rft.date=2017-01-01&rft.eissn=1474-5488&rft.volume=18&rft.issue=1&rft.spage=122&rft_id=info:doi/10.1016%2FS1470-2045%2816%2930598-8&rft_id=info%3Apmid%2F27884679&rft.externalDocID=27884679 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1470-2045&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1470-2045&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1470-2045&client=summon |